Perthpest/others: I believe that NEUREN is in the process of looking to find respective partner(s) for the ROW and therefore (IMO) BIG Pharma companies with the necessary distribution power should be the focus, i.e. primarily BIG PHARMA with some exposure/know-how in rare diseases.
Therefore, perhaps among the following (always in alphabetical order):
USA companies: AbbVie, Amgen, Moderna, Pfizer
European companies: GSK, Novo Nordisk, Sanofi, Roche (Genentech in the US...)
Asia: Takeda
I am sure I am missing a few potential ones ! Comments most welcome as always.
wasa
Perthpest/others: I believe that NEUREN is in the process of...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |